Zhejiang Cancer Hospital
🇨🇳China
Clinical Trials
245
Active:7
Completed:33
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:18
Phase 2:123
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (208 trials with phase data)• Click on a phase to view related trials
Phase 2
123 (59.1%)Not Applicable
39 (18.8%)Phase 3
19 (9.1%)Phase 1
18 (8.7%)Phase 4
7 (3.4%)Early Phase 1
2 (1.0%)a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .
Phase 2
Not yet recruiting
- Conditions
- Cervical Cancer Stage IVACervical Cancer Metastatic
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT07035808
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: pyrotinib dalpiciclib letrozole
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT07014410
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients
Not Applicable
Recruiting
- Conditions
- Hypotension on InductionOld Age
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT06968091
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Phase 2
Not yet recruiting
- Conditions
- BTK InhibitorsFollicular LymphomaImmunochemotherapy
- Interventions
- Drug: ZGCVP
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06918015
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SH-LPS System in Preoperative Planning for Liver Resection
Phase 2
Not yet recruiting
- Conditions
- Liver Tumor; Surgery3D PrintingPreoperative Planning
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06911086
- Prev
- 1
- 2
- 3
- 4
- 5
- 49
- Next
News
No news found